Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$568.06 +5.0%	$583.56	$428.76 ▼ $678.21	$33.02B	0.39	322,606 shs	385,885 shs
ILMN Illumina	$91.52 +1.0%	$81.37	$68.70 ▼ $156.66	$14.34B	1.32	2.13 million shs	2.30 million shs
VEEV Veeva Systems	$281.40 +0.4%	$251.28	$177.41 ▼ $291.69	$45.80B	0.99	1.15 million shs	886,456 shs
WST West Pharmaceutical Services	$222.85 +2.8%	$214.04	$187.43 ▼ $352.33	$15.57B	1.09	725,028 shs	575,617 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+5.05%	+5.06%	-3.33%	-2.67%	+28.93%
ILMN Illumina	+1.00%	+2.29%	+13.87%	+10.49%	-16.98%
VEEV Veeva Systems	+0.51%	+0.01%	+20.56%	+19.48%	+50.77%
WST West Pharmaceutical Services	+2.67%	+2.14%	+8.36%	-0.87%	-32.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.4144 of 5 stars	4.5	4.0	0.0	0.0	2.5	1.7	2.5
ILMN Illumina	4.8875 of 5 stars	4.2	5.0	0.0	4.2	2.0	3.3	1.3
VEEV Veeva Systems	3.7158 of 5 stars	2.3	3.0	0.0	2.9	2.9	3.3	0.6
WST West Pharmaceutical Services	4.7901 of 5 stars	3.4	5.0	1.7	3.2	2.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.05	Buy	$729.93	28.50% Upside
ILMN Illumina	2.47	Hold	$127.39	39.19% Upside
VEEV Veeva Systems	2.52	Moderate Buy	$269.80	-4.12% Downside
WST West Pharmaceutical Services	2.89	Moderate Buy	$320.00	43.59% Upside

Current Analyst Ratings Breakdown

Latest VEEV, ILMN, WST, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/24/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$77.00 ➝ $85.00
6/24/2025	WST West Pharmaceutical Services	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$245.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	ILMN Illumina	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$87.00 ➝ $99.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/2/2025	VEEV Veeva Systems	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$280.00 ➝ $295.00
5/30/2025	VEEV Veeva Systems	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$265.00 ➝ $329.00
5/29/2025	VEEV Veeva Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$285.00 ➝ $300.00
5/29/2025	VEEV Veeva Systems	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$285.00 ➝ $310.00
5/29/2025	VEEV Veeva Systems	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$217.00 ➝ $230.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	15.40	$3.12 per share	182.04	$90.49 per share	6.28
ILMN Illumina	$4.37B	3.31	$4.74 per share	19.32	$14.96 per share	6.12
VEEV Veeva Systems	$2.75B	16.74	$4.79 per share	58.77	$38.01 per share	7.40
WST West Pharmaceutical Services	$2.89B	5.53	$9.27 per share	24.05	$37.04 per share	6.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	35.04	52.36	0.98	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
ILMN Illumina	-$1.22B	-$6.07	N/A	17.74	1.78	-22.25%	25.54%	8.62%	8/5/2025 (Estimated)
VEEV Veeva Systems	$714.14M	$4.72	59.62	60.65	2.20	27.34%	13.96%	11.38%	8/27/2025 (Estimated)
WST West Pharmaceutical Services	$492.70M	$6.37	34.98	28.35	5.33	16.13%	18.23%	13.51%	7/24/2025 (Estimated)

Latest VEEV, ILMN, WST, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/28/2025	Q1 2026	VEEV Veeva Systems	$1.74	$1.97	+$0.23	$1.37	$728.38 million	$759.04 million
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	ILMN Illumina	$0.96	$0.97	+$0.01	$0.82	$1.03 billion	$1.04 billion
4/24/2025	Q1 2025	WST West Pharmaceutical Services	$1.22	$1.45	+$0.23	$1.23	$685.24 million	$698.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
VEEV Veeva Systems	N/A	N/A	N/A	N/A	N/A
WST West Pharmaceutical Services	$0.84	0.38%	N/A	13.19%	N/A

Latest VEEV, ILMN, WST, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	WST West Pharmaceutical Services	quarterly	$0.21	0.39%	7/30/2025	7/30/2025	8/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
ILMN Illumina	0.63	1.86	1.48
VEEV Veeva Systems	N/A	4.60	4.60
WST West Pharmaceutical Services	0.08	2.77	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
ILMN Illumina	89.42%
VEEV Veeva Systems	88.20%
WST West Pharmaceutical Services	93.90%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
ILMN Illumina	0.17%
VEEV Veeva Systems	10.30%
WST West Pharmaceutical Services	0.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
ILMN Illumina	9,030	158.30 million	158.03 million	Optionable
VEEV Veeva Systems	7,291	163.41 million	146.58 million	Optionable
WST West Pharmaceutical Services	10,600	71.85 million	71.44 million	Optionable

VEEV, ILMN, WST, and ARGX Headlines

Recent News About These Companies

Barclays Initiates Coverage of West Pharmaceutical Services (WST) with Equal-Weight Recommendation

June 25 at 6:44 AM | msn.com

WST - West Pharmaceutical Services Inc News - Morningstar

June 25 at 1:44 AM | morningstar.com

Contact Levi & Korsinsky by July 7, 2025 Deadline to Join Class Action Against West Pharmaceutical Services, Inc. (WST)

June 24 at 4:12 PM | globenewswire.com

WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 24 at 4:00 PM | globenewswire.com

Deadline Alert: West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

June 24 at 1:00 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

June 24 at 11:04 AM | globenewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of West Pharmaceutical Services, Inc.(WST) Shareholders

June 24 at 9:00 AM | prnewswire.com

Barclays Initiates Coverage on West Pharmaceutical Services (NYSE:WST)

June 24 at 8:25 AM | marketbeat.com

WST IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important July 7 Deadline in Securities Class Action – WST

June 23 at 6:19 PM | globenewswire.com

Lost Money on West Pharmaceutical Services, Inc.(WST)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

June 23 at 4:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST

June 23 at 10:50 AM | globenewswire.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

June 23 at 10:20 AM | markets.businessinsider.com

West Pharmaceutical Services, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - WST

June 23 at 9:00 AM | prnewswire.com

Sawgrass Asset Management LLC Invests $6.33 Million in West Pharmaceutical Services, Inc. (NYSE:WST)

June 23 at 6:28 AM | marketbeat.com

Envestnet Portfolio Solutions Inc. Decreases Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

June 23 at 3:52 AM | marketbeat.com

WST DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WST

June 22 at 12:55 PM | markets.businessinsider.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West ...

June 22 at 11:32 AM | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST

June 22 at 10:00 AM | prnewswire.com

Praxis Investment Management Inc. Invests $681,000 in West Pharmaceutical Services, Inc. (NYSE:WST)

June 22 at 4:40 AM | marketbeat.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

June 21, 2025 | markets.businessinsider.com

WST DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WST

June 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VEEV, ILMN, WST, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$568.06 +27.30 (+5.05%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$563.80 -4.26 (-0.75%)

As of 08:12 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Illumina NASDAQ:ILMN

$91.52 +0.91 (+1.00%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$91.49 -0.03 (-0.03%)

As of 08:11 AM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Veeva Systems NYSE:VEEV

$281.40 +1.10 (+0.39%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$281.27 -0.13 (-0.05%)

As of 08:11 AM Eastern

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

West Pharmaceutical Services NYSE:WST

$222.85 +6.15 (+2.84%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$225.03 +2.18 (+0.98%)

As of 08:07 AM Eastern

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time